Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo
نویسندگان
چکیده
The present work describes the engineering of anti-PSMA peptide-decorated exosome mimetics (EMs) targeting advanced prostate cancer (PC). targeted EMs were produced from peptide, WQPDTAHHWATL, expressing U937 monoblastic cells, followed by successive extrusion cycles. engineered nanosized, at a high yield, and displayed exosomal markers monocytes proteins on their surface. As anticipated, PSMA-EMs showed increased cellular internalization in PSMA positive PC cell lines (LNCaP C4-2B), compared to unmodified EMs. Most importantly, higher tumour was observed solid C4-2B tumours, following intravenous administration, confirming ability vivo. Overall, our study indicates that peptide-targeted can be promising drug delivery system for PC.
منابع مشابه
Supernatant Metabolites from Halophilic Archaea to Reduce Tumorigenesis in Prostate Cancer In-vitro and In-vivo
Halophilic archaea are known as the novel producers of natural products and their supernatant metabolites could have cytotoxic effects on cancer cells. In the present study, we screened the anticancer potential of supernatant metabolites from eight native haloarchaeal strains obtained from a culture collection in Iran. Five human cancer cell lines including breast, lung, prostate and also human...
متن کاملSupernatant Metabolites from Halophilic Archaea to Reduce Tumorigenesis in Prostate Cancer In-vitro and In-vivo
Halophilic archaea are known as the novel producers of natural products and their supernatant metabolites could have cytotoxic effects on cancer cells. In the present study, we screened the anticancer potential of supernatant metabolites from eight native haloarchaeal strains obtained from a culture collection in Iran. Five human cancer cell lines including breast, lung, prostate and also human...
متن کاملIn vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer
Docetaxel (DOC) is used for the first-line treatment of castration resistant prostate cancer (CPRC). However, the therapeutic effects are limited, only about one half of patients respond to the therapy and severe side effects possibly lead to discontinuation of treatment. Therefore, actual research is focused on the development of new DOC-based combination treatments. In this study we investiga...
متن کاملTargeting advanced prostate cancer.
Advances in prostate cancer therapies are shifting from a focus on cancer epithelial cells to targeting the tumor environment. In a review published in the September 13 issue of the Journal, researchers examined the most promising therapies for metastatic castrate-resistant prostate cancer (mCRPC) — when the disease progresses despite low levels of tumor-fueling hormones.“We study drugs for tre...
متن کاملGenetically engineered mouse models of prostate cancer.
Despite major improvement in treatment of early stage localised prostate cancer, the distinction between indolent tumors and those that will become aggressive, as well as the lack of efficient therapies of advanced prostate cancer, remain major health problems. Genetically engineered mice (GEM) have been extensively used to investigate the molecular and cellular mechanisms underlying prostate t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Controlled Release
سال: 2021
ISSN: ['1873-4995', '0168-3659']
DOI: https://doi.org/10.1016/j.jconrel.2020.12.017